BioSpace News Archive

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced its first quarter 2022 financial results.

IRADIMED CORPORATION, announced that John Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022.

Zymergen Inc., announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant’s next-generation platform to develop breakthrough medicines.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.

Protalix BioTherapeutics, Inc. announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced the publication of updated results from the clinical trial of the lead asset from its ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces updated interim safety and efficacy data from its Phase 1/1b AURELIO-03 dose escalation study of theIL-2/IL-15 receptor βγ superagonist, SOT101, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced an upcoming poster presentation of preliminary data from its ongoing Phase 2 VERSATILE-002 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Elevar Therapeutics, Inc. announced its Phase 2 clinical trial evaluating rivoceranib, an orally administered tyrosine kinase inhibitor, demonstrated clinical effectiveness in patients with progressive recurrent or metastatic adenoid cystic carcinoma.

Mereo BioPharma Group plc announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.